Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSHA-105 in SLC13A5 Citrate Transporter Disorder
NCT07102524Phase 2Recruiting
- Sponsor
- TESS Research Foundation
- Start
- Jul 2026
- Primary completion
- Dec 2030
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TSHA-105 in SLC13A5 Citrate Transporter Disorder (SLC13A5), sponsored by TESS Research Foundation. Primary endpoint: Safety and Tolerability at 5 years. Started Jul 2026; status: recruiting.
02
Drugs
TSHA-105
03
Conditions
SLC13A5 Citrate Transporter Disorder (SLC13A5)
Beyond the preview
Go deeper on NCT07102524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102524.